A new study of patients with diffuse large B-cell lymphoma (DLBCL) suggests that event-free status at 2 years post-treatment is a useful endpoint both for research and for patient counseling.
A phase II trial of mogamulizumab showed that the agent has meaningful antitumor activity in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma, and acceptable toxicity.
MolecularMD and Novartis are working on a diagnostic test to help determine which chronic myeloid leukemia patients may be candidates to stop taking nilotinib.
A breath test that looks for carbonyl volatile organic compounds could help distinguish between benign and malignant nodules, and be used as an adjunct to CT scans in lung cancer diagnosis.
Contrary to some previous research as well as popular belief, living underneath or near to power lines as a child may not have any notable effect on childhood leukemia risk, according to a new case-control study conducted in the United Kingdom.
A study in mice showed that antioxidant supplementation increases tumor progression and reduced survival in Braf- and Kras-induced lung cancer.
A score based on an epigenetic signature of hematopoietic stem cells (HSCs) is highly prognostic for patients with acute myeloid leukemia (AML), according to a new study.
The use of a microRNA signature classifier assay was found to have high predictive, diagnostic, and prognostic value in a lung cancer screening trial in Italy. Adding the plasma microRNA test to low-dose CT screening reduced false positive rates.
A new review describes how increasing prices on cigarettes could be one of the most effective methods in the coming decades for reducing tobacco-related mortality.
After significant improvement in progression-free survival with ibrutinib over ofatumumab, an independent data monitoring board has recommended stopping a phase III trial involving patients with relapsed or refractory CLL or SLL.